Research & Clinical Trials

As the only national nonprofit advocacy organization focused on hereditary breast and ovarian cancer, FORCE has a strong commitment to promoting research.

| More

Research & Clinical Trials
Toggle Menu

NCT01233505

Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

Study identifier: NCT01233505
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbott)

Eligibility:

Patients with a BRCA-related malignancy and/or:

  • Patients without a known BRCA mutation must have a probability of harboring a BRCA gene mutation as assessed by BRCAPRO computer program
  • Patients with a probability of having genetic mutation ≥ 20% or a BRCA mutation based on a non-Myriad test, must have a formal BRCA testing by Myriad Genetic Laboratories
  • Patients with known deleterious BRCA 1 or 2 mutation or a mutation of uncertain significance

Patients who refuse BRCA testing not allowed unless they have another acceptable histology

  • First- or second-line metastatic colorectal cancer
  • Any-line metastatic mucinous ovarian cancer
  • Any line of other metastatic gastrointestinal malignancies in which oxaliplatin has shown some activity (i.e., gastric or pancreatic adenocarcinoma)

May have brain metastases that have been treated and stable for 2 months

Type of study:

Phase I

Treatment:

Patients receive oral veliparib twice daily and oral capecitabine twice daily on 1-7 and 15-21, and oxaliplatin IV over 2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Study site:

Wisconsin
Madison
University of Wisconsin Hospital and Clinics
Contact: George Wilding 608-263-3961 wrs@medicine.wisc.edu  

 

Page updated 06/10/13